Royalty Pharma AI Stock Analysis
Royalty Pharma (RPD) AI Stock Analysis
Royalty Pharma
(XETRA:RPD)
No summary available
Royalty Pharma (RPD) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 30.86B
- Dividend Yield
- 1.36%
- Average Volume (3M)
- 68
- Price to Earnings (P/E)
- 41.0
- Beta (1Y)
- 0.32
- Revenue Growth
- 5.84%
- EPS Growth
- -16.96%
- Country
- Germany
- Employees
- 100
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Royalty Pharma Business Overview & Revenue Model
Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...
Royalty Pharma Earnings Call Summary
The call was strongly positive. Royalty Receipts and Portfolio Receipts grew 9% in the quarter, year-to-date Royalty Receipts grew 12%, returns remained attractive, guidance was raised for the third consecutive quarter, and the company reported substantial clinical, regulatory, pipeline, capital allocation, and business-development momentum. The principal negatives were the pelacarsen Phase III failure and $150 million noncash impairment, product declines in Promacta and Imbruvica, and lower expected milestone receipts, but management emphasized protective deal structures and continued portfolio growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Royalty Pharma now expects 2026 Portfolio Receipts to be in the range of $3.5 billion to $3.55 billion, up from $3.4 billion to $3.5 billion previously, with growth in Royalty Receipts of around 10% to 11% compared with 7% to 10% previously; milestones and other contractual receipts are expected to decrease from $128 million in 2025 to approximately $65 million in 2026, operating and professional costs are expected to be in the range of 5.5% to 6% of portfolio receipts, and interest paid is expected to be around $350 million to $360 million, with interest paid anticipated to be a de minimis amount in Q4. The company expects to deploy around $2.5 billion per year over the long-term, deliver strong low volatility top and bottom line growth through 2030 and beyond, and generate an IRR and return on invested capital in the mid-teens and return on invested equity in the 20%-plus range; its development stage pipeline has the potential to add peak royalties of more than $1.7 billion, while Mimrylo has peak annual sales of between $1 billion and $2 billion and an expected unlevered IRR in the low double-digit percentage range, and Zoryve is expected to grow by more than 40% in 2026 to over $0.5 billion, with Arcutis’ peak sales estimate of $2.3 billion to $3 billion.
Royalty Pharma Risk Analysis
Royalty Pharma disclosed 58 risk factors in its most recent earnings report. Royalty Pharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksRoyalty Pharma Peers Comparison
Overall Rating
KNSA80Outperform
CORT72Outperform
PBH65Neutral
LQDA63Neutral
SVA43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | $7.57B | 67.36 | 17.27% | ― | 58.19% | 192.34% | |
| 72Outperform | $7.98B | 48.63 | 22.94% | ― | 30.02% | 48.80% | |
| 65Neutral | $2.19B | 14.17 | 8.19% | ― | 5.10% | -19.73% | |
| 63Neutral | $5.17B | -55.74 | -116.64% | ― | 798.44% | 27.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $460.27M | -7.79 | -0.94% | ― | 8.78% | -227.47% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:RPD | Royalty Pharma PLC | 62.32 | 29.91 | 92.26% | |
| CORT | Corcept Therapeutics | 72.94 | -2.18 | -2.90% | |
| PBH | Prestige Consumer Healthcare | 46.19 | -12.79 | -21.69% | |
| SVA | Sinovac Biotech | 6.47 | 0.00 | 0.00% | |
| KNSA | Kiniksa Pharmaceuticals Ltd. Class A | 96.33 | 54.93 | 132.68% | |
| LQDA | Liquidia Technologies | 57.41 | 29.01 | 102.15% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
